Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, March 27, 2025 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company and partner Eisai will present data on real-world use of lecanemab at the 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), to be held in Vienna, Austria, and virtually April 1-5. In total, lecanemab will be featured in six presentations and exidavnemab in one presentation.
Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai. The anti-amyloid beta (Aβ) protofibril antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease.
At AD/PD, Johanna Fälting, BioArctic's Chief R&D Officer, will hold one oral presentation on exidavnemab, the company's proprietary drug candidate aimed at treating synucleinopathies. BioArctic will also present one poster related to lecanemab in Alzheimer's disease.
In addition to BioArctic's presentations, Eisai will present four oral presentations and one poster presentation on lecanemab. These presentations will include the latest findings from real-world clinical evidence of lecanemab in the United States, efficacy and safety outcomes in apolipoprotein E ε4 (ApoEε4) heterozygous carriers and non-carriers in the Phase 3 Clarity AD clinical study, and a subgroup analysis of Clarity AD open label extension study in the Asian region.
Eisai will sponsor two symposiums on Alzheimer's Disease.
Bridging the Gap in Alzheimer's Disease: From Pathophysiology to Treatment Strategy featuring three leading global experts in the field of Alzheimer's Disease, Dr. Dennis J. Selkoe (chair), Dr. Michael Heneka, and Dr. Miia Kivipelto. The symposium aims to enhance understanding by providing expert insights into the key drivers and mechanisms of Alzheimer's Disease pathophysiology and neurodegeneration, the rationale for targeted approaches to anti-amyloid-β therapies, lessons from past drug development, and emerging treatment strategies.
Transforming Outcomes in Early AD: A Focus on Intervention and Management featuring prominent clinical experts in the field of Alzheimer's Disease. The symposium will provide updates and insights into early Alzheimer's Disease treatment from various perspectives, as well as information on future treatment directions.
Presentations by BioArctic and Eisai
Oral presentations
| Asset in development, Session, Time | Presentation Title |
| LecanemabAbeta targeting therapies in ADThursday, April 3, 15:05 - 15:20 | Real-world evidence of lecanemab use in the United States |
| Lecanemab Abeta and Tau immunotherapiesSaturday, April 5, 11:10 - 11:25 | Lecanemab-associated amyloid-beta protofibril in CSF is a proximal biomarker of neurodegeneration unlike other plaque-associated biomarkers. |
| E2814 & LecanemabTauopathies: Challenges in targeting TauSaturday, April 5, 12:40 - 12:55 | Clinical trial design for concurrent anti-amyloid and anti-Tau antibody therapy for sporadic Alzheimer's disease |
| ExidavnemabAdvances in PD, LBD and MSA drug developmentSaturday, April 5, 16:40 - 16:55 | Exidavnemab (BAN0805) offers opportunities as a potential modifying therapy in several synucleinopathies. Johanna Fälting, Chief R&D Officer, BioArctic |
| LecanemabAdvances in AD drug developmentSaturday, April 5, 16:40 - 16:55 | Lecanemab for treatment of individuals with early Alzheimer's disease (AD): Results in apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes |
Poster presentations
| Asset in Development, Topic, Poster Number | Presentation Title |
| Lecanemab SHIFT 02-442April 2 - 3 and 4 - 5 | Lecanemab demonstrates highly selective binding to a-beta protofibrils isolated from Alzheimer's disease brains Presented by BioArctic |
| LecanemabVirtual EP - 046 | Lecanemab long-term efficacy and safety in the Asia region: A subgroup analysis from the phase 3 Clarity AD trial |
Eisai-Sponsored Symposium
| Time | Title, Presenter |
| Industry Symposium 09 Thursday, April 3, 18:40-20:15Hall E | Bridging the gap in Alzheimer's disease treatment: From pathophysiology to treatment strategyDennis J. Selkoe, Michael Heneka, Miia Kivipelto |
| Industry Symposium 12Friday, Apr 4, 13:50 - 15:50 | Transforming Outcomes in Early AD: A Focus on Intervention and Management. Multidisciplinary coordination for early Alzheimer's disease: Insights from the first treatment centres |
---
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
The information was released for public disclosure, through the agency of the contact persons below, on March 27, 2025, at 08.00 CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.com
Phone: +46 70 410 71 80
Charlotte af Klercker, Senior Director Sustainability and Communications
E-mail: charlotte.afklercker@bioarctic.com
Phone: +46 73 515 09 70
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.